Page 6

TOP_August2010_FINAL_TOP 8/10/10 3:22 PM Page 4

EDITOR’S LETTER

T

his issue of The Oncology Pharmacist spotlights the work of two of our board members—John Valgus and LeAnn Norris. Both of them have chosen to combine clinical and academic work in their own careers and serve as role models for pharmacy students and residents while providing the excellent clinical services of their institutions. Patrick Medina, John’s article, based on a presPharmD, BCOP entation at the 2009 American Editor-in-Cheif Society of Health-System Pharmacists’ midyear clinical meeting, provides excellent, practical suggestions for how preceptors can improve the learning experience for their trainees. As LeAnn discusses in an interview, her own decision to specialize in oncology was partly the result of working with Lew Iacovelli, another one of our board members, who was her role model and mentor. LeAnn won the New Practitioner Award at this year’s meeting of the

PUBLISHING STAFF Publisher Philip Pawelko phil@greenhillhc.com Editorial Director Karen Rosenberg karen@greenhillhc.com Associate Editor Dawn Lagrosa dawn@greenhillhc.com Director, Client Services John W. Hennessy john@greenhillhc.com Production Manager Stephanie Laudien Business Manager Blanche Marchitto blanche@greenhillhc.com Executive Administrator Andrea Boylston Circulation Department circulation@greenhillhc.com Editorial Contact: Telephone: 732-992-1891 Fax: 732-656-7938

GH Green Hill Healthcare Communications

, LLC ™

Your Innovative Partners in Medical Media

241 Forsgate Drive, Suite 205C Monroe Twp, NJ 08831 The Oncology Pharmacist®, ISSN 1944-9607 (print); ISSN 1944-9593 (online) is published 8 times a year by Green Hill Healthcare Communications, LLC, 241 Forsgate Drive, Suite 205C, Monroe Twp, NJ 08831. Telephone: 732.656.7935. Fax: 732.656.7938. Copyright ©2010 by Green Hill Healthcare Communications LLC. All rights reserved. The Oncology Pharmacist® logo is a registered trademark of Green Hill Healthcare Communications, LLC. No part of this publication may be reproduced or transmitted in any form or by any means now or hereafter known, electronic or mechanical, including photocopy, recording, or any informational storage and retrieval system, without written permission from the Publisher. Printed in the United States of America. EDITORIAL CORRESPONDENCE should be addressed to EDITORIAL DIRECTOR, The Oncology Pharmacist®, 241 Forsgate Drive, Suite 205C, Monroe Twp, NJ 08831. E-mail: editorial@greenhillhc.com. YEARLY SUBSCRIPTION RATES: United States and possessions: individuals, $105.00; institutions, $135.00; single issues $17.00. Orders will be billed at individual rate until proof of status is confirmed. Prices are subject to change without notice. Correspondence regarding permission to reprint all or part of any article published in this journal should be addressed to REPRINT PERMISSIONS DEPARTMENT, Green Hill Healthcare Communications, LLC, 241 Forsgate Drive, Suite 205C, Monroe Twp, NJ 08831. The ideas and opinions expressed in The Oncology Pharmacist® do not necessarily reflect those of the Editorial Board, the Editorial Director, or the Publisher. Publication of an advertisement or other product mention in The Oncology Pharmacist® should not be construed as an endorsement of the product or the manufacturer’s claims. Readers are encouraged to contact the manufacturer with questions about the features or limitations of the products mentioned. Neither the Editorial Board nor the Publisher assumes any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other healthcare professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Every effort has been made to check generic and trade names, and to verify dosages. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to the Editorial Director.

4

August 2010 I Vol 3, No 5

CONTENTS FEATURE ARTICLES 6 ASCO: Prostate Cancer Denosumab prevents more skeletal events than zoledronic acid in men with prostate cancer and bone metastases Cabazitaxel improves overall survival in patients with hormone-refractory prostate cancer

8 ASCO: Pain Management Fentanyl nasal spray beats oral opioid for control of breakthrough cancer pain Naproxen reduces bone pain after pegfilgrastim injection

10 ASCO: Hematologic Cancers In CML, longer follow-up confirms superiority of nilotinib over imatinib

13 ASCO: Skin Cancer New monoclonal antibody treatment offers hope for treatment of metastatic melanoma

14 Continuing Education

Hematology/Oncology Pharmacy Association, a tribute to her own hard work and Lew’s excellence as a teacher and practitioner. This issue also features reports from the recent annual meeting of the American Society of Clinical Oncology. The thousands of studies presented there in just a few days is ample evidence of the enormous strides being made in basic and clinical research in oncology. To help readers keep up with the daunting amount of cancerrelated information released daily, we are adding daily news updates and other new features to The Oncology Pharmacist website (www.theoncologypharmacist.com). We hope you will visit the website and share your thoughts on the issues of the day. For those involved in research themselves, we invite contributions of original research as well as review articles, case reports, and articles on oncology pharmacy practice to our upcoming peer-reviewed publication, the Journal of Hematology/Oncology Pharmacy, which will provide a new outlet for oncology pharmacists to share their findings with their peers. Please send inquiries about manuscript preparation to editorial@ greenhillhc.com. ●

August 2010 • Vol 3, No 5 18 Gastrointestinal Cancers Nab-paclitaxel plus gemcitabine may help patients with advanced pancreatic cancer

22 Breast Cancer Postmenopausal women with breast cancer receiving letrozole or anastrozole may be at increased risk for bone loss

DEPARTMENTS 20 Oncology Drug Codes Colorectal cancer

27 Financial Planning Investment advisor or financial planner for your investments: who is right for you?

27 News Notes 28 International News 25th Anniversary EAU Annual Congress; 15th Congress of the EHA

29 Meetings

Perspectives on idiopathic thrombocytopenia purpura: ASH 2009

18 Pharmacy Careers LeAnn Norris Wins New Practitioner Award

www.theoncologyPharmacist.com

Profile for The Oncology Pharmacist

August 2010, Vol 3, No 5  

The Oncology Pharmacist

August 2010, Vol 3, No 5  

The Oncology Pharmacist

Advertisement